ROG 📈 Roche Holding - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012032048
ROG: Pharmaceuticals, Diagnostics, Cancer, Diabetes, Covid-19, Tests, Instruments
Roch Holding AG operates as a multinational healthcare company, with a significant presence in the pharmaceuticals and diagnostics sectors, spanning across various regions including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company's pharmaceutical product portfolio is diverse, covering therapeutic areas such as anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune diseases, neurological disorders, ophthalmology, respiratory disorders, and transplantation. This extensive range of products underscores the company's commitment to addressing a wide array of medical needs. Furthermore, Roche is continually developing new products for various therapeutic areas, indicating a strong focus on research and development.
In the diagnostics sector, Roche offers a comprehensive range of in vitro tests designed for the diagnosis of numerous diseases, including but not limited to cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company provides diagnostic instruments and digital health solutions, reflecting its effort to integrate technology into healthcare solutions. This not only aids in the accurate diagnosis of diseases but also contributes to the development of personalized medicine. The company's strategic collaborations, such as its discovery collaboration with Flare Therapeutics Inc., leveraging proteomic and mass spectrometry platforms to discover novel small molecules targeting transcription factor targets in oncology, highlight its innovative approach to drug discovery.
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG has a long history of contributing to the global healthcare industry. With a web presence at https://www.roche.com, the company maintains transparency and accessibility for its stakeholders. Listed with the ISIN CH0012032048 as a common stock, and categorized under the GICS Sub Industry: Pharmaceuticals, Roche Holding AG is a significant player in the pharmaceutical industry, with a market presence that is both substantial and influential.
Additional Sources for ROG Stock
ROG Stock Overview
| Market Cap in USD | 225,734m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
ROG Stock Ratings
| Growth 5y | -8.91% |
| Fundamental | 68.3% |
| Dividend | 58.4% |
| Rel. Strength Industry | 527 |
| Analysts | - |
| Fair Price Momentum | 260.88 CHF |
| Fair Price DCF | 638.60 CHF |
ROG Dividends
| Dividend Yield 12m | 3.57% |
| Yield on Cost 5y | 3.45% |
| Annual Growth 5y | 1.30% |
| Payout Consistency | 98.8% |
ROG Growth Ratios
| Growth Correlation 3m | -44.2% |
| Growth Correlation 12m | 71% |
| Growth Correlation 5y | -52.3% |
| CAGR 5y | -0.94% |
| CAGR/Mean DD 5y | -0.05 |
| Sharpe Ratio 12m | 0.45 |
| Alpha | 2.81 |
| Beta | 0.22 |
| Volatility | 18.26% |
| Current Volume | 1326.3k |
| Average Volume 20d | 1095.4k |
As of January 20, 2025, the stock is trading at CHF 265.40 with a total of 1,326,347 shares traded.
Over the past week, the price has changed by +0.19%, over one month by +7.58%, over three months by -2.75% and over the past year by +13.24%.
Yes, based on ValueRay Fundamental Analyses, Roche Holding (SW:ROG) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 68.31 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ROG as of January 2025 is 260.88. This means that ROG is currently overvalued and has a potential downside of -1.7%.
Roche Holding has no consensus analysts rating.
According to ValueRays Forecast Model, ROG Roche Holding will be worth about 281.9 in January 2026. The stock is currently trading at 265.40. This means that the stock has a potential upside of +6.23%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 303.4 | 14.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 281.9 | 6.2% |